
APYX Stock Forecast & Price Target
APYX Analyst Ratings
Bulls say
Apyx Medical Corp is poised for growth, with Surgical Aesthetics revenue projected to reach between $43.0 million and $45.0 million, reflecting a year-over-year increase of 14% at the midpoint and a positive revision in full-year revenue guidance to $50.5 million to $52.5 million. The recent launch of the AYON system and the resulting 19% uptick in Surgical Aesthetics revenue, alongside increased demand for skin tightening procedures linked to weight-loss trends, further support a favorable financial outlook. Additionally, Apyx's revenue estimates for FY2026 have been raised to $58.0 million, indicating a strong market position fueled by innovation and shifting consumer needs.
Bears say
Apyx Medical Corp has revised its Original Equipment Manufacturing (OEM) sales guidance down to approximately $7.5 million, reflecting a decline of around $0.5 million from previous projections, primarily attributed to reduced sales volumes to existing customers. The company's stock price has struggled since peaking at $17.40 per share in September 2021, largely due to the lingering effects of an FDA warning letter issued in March 2022 and heightened competition in the aesthetic medicine sector driven by the increasing use of GLP-1 medications. Additionally, Apyx Medical's financial position shows a decrease in cash and cash equivalents, falling to $25.1 million at the end of Q3 2025 from $29.3 million in Q2 2025, which raises concerns regarding operational liquidity amid revenue pressures.
This aggregate rating is based on analysts' research of Apyx Medical Corp and is not a guaranteed prediction by Public.com or investment advice.
APYX Analyst Forecast & Price Prediction
Start investing in APYX
Order type
Buy in
Order amount
Est. shares
0 shares